Healthcare

Medical Developments International, the maker of the emergency pain-relief product Penthrox, has spent years being defined by the gap between its promising flagship and its modest financial scale. Its 2026 full-year result, released on 21 August, offered evidence that the commercial engine is at …

Amplia Therapeutics has become one of the more closely followed clinical-stage biotechs on the ASX, and 2026 has given watchers plenty to digest. The company is developing narmafotinib, a focal adhesion kinase (FAK) inhibitor, with its lead effort aimed at pancreatic cancer, one of …

Orthocell's FY2026 result, reported on 12 July 2026, showed total revenue of $13.2 million, up 44% year on year, with the June quarter contributing $3.8 million. The most watched figure was US Remplir revenue, which reached about $330,000 in the June quarter, a 10% …

That combination, a high-value late-stage trial plus a growing web of partnerships, is why Dimerix remains one of the most closely followed names on the ASX healthcare board.

In February 2025 Mayne agreed to be acquired by US-based Cosette Pharmaceuticals for AUD 7.40 per share, valuing the company at about AUD 672 million. The deal unravelled over 2025: Cosette sought to walk away citing a material adverse change, the NSW Supreme Court …

The reason to look now is a full-year result that combined steady core growth with a genuine catalyst — regulatory clearance for its new pathogen-detection platform, CORIS — even as the market reaction was cautious.

The appeal has always been the economics. Pro Medicus sells cloud-based software with minimal incremental cost, so each new contract flows heavily to profit. FY26 illustrated thatLeveragevividly.